Table 2.
Trials of antiresorptive agents for preventing CTIBL in postmenopausal women with breast cancer (adapted from Hadji et al. 62)
| Antiresorptive agent (trial) | n | BMaD study, n | Dosing | Treatment duration, years |
|---|---|---|---|---|
| Zoledronic acid (ZO‐FAST) | 1065 | 1065 | 4 mg iv q6mo | 5 |
| Zoledronic acid (Z‐FAST) | 602 | 602 | 4 mg iv q6mo | 5 |
| Zoledronic acid (E‐ZO‐FAST) | 527 | 527 | 4 mg iv q6mo | 5 |
| Zoledronic acid (N03CC) | 558 | 395 | 4 mg iv q6mo | 5 |
| Denosumab (HALT‐BC) | 252 | 252 | 60 mg sc q6mo | 2 |
| Denosumab (ABCSG‐18) | 3425 | 1872 | 60 mg sc q6mo | 5 |
| Denosumab 72 | 1468 | 1468 | 60 mg sc q6mo | 2 |
| Risedronate (SABRE) | 154 | 111 | 35 mg po/week | 2 |
| Risedronate | 87 | 87 | 35 mg po/week | 5 |
| Clodronate | 61 | 61 | 1600 mg po/day | 3 |
| Risedronate (ARBI) | 213 | 70 | 35 mg po/week | 2 |
| Risedronate (IBIS‐II) | 613 | 59 | 35 mg po/week | 5 |
| Ibandronate (ARIBON) | 131 | 50 | 150 mg po/month | 2 |
| Risedronate | 118 | 11 | 35 mg po/week | 1 |
BMaD: bone mass density; iv: intravenous; sc: subcutaneous; po: per os; q6month: every 6 months